Patupilone (EPO906, Epothilone B)

製品コードS1364

Patupilone (EPO906, Epothilone B)化学構造

分子量(MW):507.68

Patupilone (EPO906, Epothilone B) は、一種のパクリタキセ(paclitaxel)のようなマイクロチューブ安定剤で、 EC0.01が1.8μM。臨床2期。

サイズ 価格 在庫  
USD 315 あり
USD 88 あり
USD 151 あり
USD 264 あり
USD 592 あり

カスタマーフィードバック(3)

  • Oncotarget, 2015, 6(13):10893-907.. Patupilone (EPO906, Epothilone B) purchased from Selleck.

    J Cancer Res Clin Oncol, 2016, 142(11):2281-9.. Patupilone (EPO906, Epothilone B) purchased from Selleck.

  • Cells were seeded in 96 well paltes, and then treated with the indicated concentration of Epothilone B for 48 h. Cell survival was measured by a standarad MTT assay.

     

     

    Dr. Helen Sadik of Johns Hopkins University. Patupilone (EPO906, Epothilone B) purchased from Selleck.

製品安全説明書

Microtubule Associated阻害剤の選択性比較

生物活性

製品説明 Patupilone (EPO906, Epothilone B) は、一種のパクリタキセ(paclitaxel)のようなマイクロチューブ安定剤で、 EC0.01が1.8μM。臨床2期。
ターゲット
Tubulin [1]
(Cell-free assay)
1.8 μM(EC0.01)
体外試験

Epothilone B shows better activity than Epothilone A. The EC0.01 of Epothilone B is 1.8 μM. Epothilone B potently inhibits cell proliferation in HCT116 cells, with IC50 of 0.8 nM. [1] Epothilone B induces mitotic arrest and displays cytotoxicity in KB3-1, KBV-1, Hela, and Hs578T cells, with IC50 of 3 nM to 92 nM. Epothilone B competes with Taxol in binding to microtubules, with IC50 of 3.3 μM. [2] In MCF-7 cells overexpressing GFP-α-tubulin, Epothilone B (3.5 nM) efficiently blocks microtubule dynamics. Meanwhile, Epothilone B induces mitotic arrest with IC50 of 3.5 nM. [3] In multiple myeloma (MM) cells, including RPMI 8226, U266, MM.1S, LR5, and MR20, Epothilone B directly suppresses proliferation with IC50 of 1 nM to 10 nM. Similarly, Epothilone B (10 nM) also induces cell cycle arrest and apoptosis. [4] A recent study reveals that, in ovarian cancer Hey cells, Epothilone B (5 nM–100 nM) enhances surface epithelial cell adhesion antigen (EpCAM), without affecting the transcription or the total cellular level of EpCAM. [5]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human LC-2-ad cell NGXKTYdIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MmnETY5pcWKrdHnvckBw\iCqdX3hckBNSy1{LXHkJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{44P2VvME[g{txO NUDUPXpPW0GQR1XS
human A431 cell NIXRR3VIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NYW5eFd2UW6qaXLpeIlwdiCxZjDoeY1idiCDNEOxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9PU45PmVvME[g{txO NHr0XXJUSU6JRWK=
human SW1710 cell M2\1[mdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MnTBTY5pcWKrdHnvckBw\iCqdX3hckBUXzF5MUCgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlE1\S1yNTFOwG0> NYXh[ZNXW0GQR1XS
human Daoy cell M{PwNWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NXv0eYxoUW6qaXLpeIlwdiCxZjDoeY1idiCGYX;5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZnwxIxiSVO1NF0zNjd|ZT2wOUDPxE1? M4HTfHNCVkeHUh?=
human BFTC-905 cell M4GzUWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M4jrSGlvcGmkaYTpc44hd2ZiaIXtZY4hSk[WQz25NFUh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF01Njl7ZT2wOUDPxE1? MnXwV2FPT0WU
human A375 cell MkfFS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NXn6VncyUW6qaXLpeIlwdiCxZjDoeY1idiCDM{e1JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OYUuODVizszN M3LabnNCVkeHUh?=
human RKO cell M1\1V2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M2LRb2lvcGmkaYTpc44hd2ZiaIXtZY4hWkuRIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Nj60O4UuODVizszN M17kW3NCVkeHUh?=
human KYSE-510 cell MnXhS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M4XVXWlvcGmkaYTpc44hd2ZiaIXtZY4hU1mVRT21NVAh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF04NjN6ZT2wOUDPxE1? MXjTRW5ITVJ?
human HLE cell M3O3c2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 Mon3TY5pcWKrdHnvckBw\iCqdX3hckBJVEViY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD16LkK2[U0xPSEQvF2= Mlv0V2FPT0WU
human MCF7 cell M1LHXWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MWnJcohq[mm2aX;uJI9nKGi3bXHuJG1ETjdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD16Lk[2[U0xPSEQvF2= MUfTRW5ITVJ?
human 786-0 cell NIrMPIZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MmjFTY5pcWKrdHnvckBw\iCqdX3hckA4QDZvMDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNVEhdk1? M4XROHNCVkeHUh?=
human TE-8 cell MlvDS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NGDvVY9KdmirYnn0bY9vKG:oIHj1cYFvKFSHLUigZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlEyOSCwTR?= MmCxV2FPT0WU
ovarian carcinoma 1A9 cell NIj3[HJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MXvJcohq[mm2b4L5JINwdmOnboTyZZRqd25iYXfhbY5{fCCxdnHybYFvKGOjcnPpco9u[SBzQUmgZ4VtdCCpcn;3eIg> MlXYNVYyOzR7Mki=
human PANC-03-27 cell NE\vSHhIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NEfXfotKdmirYnn0bY9vKG:oIHj1cYFvKFCDTlOtNFMuOjdiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkGzNkDPxE1? NELhdlRUSU6JRWK=
human VMRC-RCZ cell MlnpS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M13POmlvcGmkaYTpc44hd2ZiaIXtZY4hXk2UQz3SR3oh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjF|NjFOwG0> NH;Nd|dUSU6JRWK=
human IGROV-1 cell MX;Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NYXZR2NNUW6qaXLpeIlwdiCxZjDoeY1idiCLR2LPWk0yKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5zNU[g{txO NYn1ZnViW0GQR1XS
human MG-63 cell MmHpS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MojiTY5pcWKrdHnvckBw\iCqdX3hckBOTy14MzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNVY2KM7:TR?= NVzBRnZ[W0GQR1XS
human SIG-M5 cell MWnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Ml3oTY5pcWKrdHnvckBw\iCqdX3hckBUUUdvTUWgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlE3QSEQvF2= NF\6SI5USU6JRWK=
human NCI-H650 cell MUfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NXS5dJR6UW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFY2OCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwMUeg{txO M3HHXXNCVkeHUh?=
human PSN1 cell MVTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NXPNeFNCUW6qaXLpeIlwdiCxZjDoeY1idiCSU16xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4yPzNizszN MU\TRW5ITVJ?
human PA-1 cell MWTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MkmyTY5pcWKrdHnvckBw\iCqdX3hckBRSS1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6xO|Qh|ryP NFvBXYlUSU6JRWK=
KB-8511 cells NYrlOI1LT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NIX2UZI4OiCq Mm\YR49v[2WwdILheIlwdiC{ZYH1bZJm\CC2bzDpcohq[mm2IITo[UBoem:5dHigc4YheGGlbHn0ZZhmdC2{ZYPpd5RidnRiaIXtZY4h\XCrZHXycY9q\CClYYLjbY5wdWFiY3XscJMhU0JvOEWxNUBjgSB3MDDw[ZJk\W62IDi3NkBpeiCneIDvd5Vz\SluIFnDOVA:OC5zODFOwG0> MkntNVEyOzNyOE[=
KB-31 cells MXjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NEPZXJM4OiCq NULMVFN1S2:wY3XueJJifGmxbjDy[ZF2cXKnZDD0c{BqdmirYnn0JJRp\SCpcn;3eIghd2ZicHHjcIl1[XinbD3z[Y5{cXSrdnWgbJVu[W5iZYDp[IVzdW:rZDDjZZJkcW6xbXGgZ4VtdHNiS1KtN|Eh[nliNUCgdIVz[2WwdDCoO|IhcHJiZYjwc5N2emVr NGrOdGIyOTF|M{C4Oi=>
human BHY cell NWDXRotXT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NEi3[oZKdmirYnn0bY9vKG:oIHj1cYFvKEKKWTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNVk2KG6P M2jjU3NCVkeHUh?=
human BB30-HNC cell Ml7kS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NUPRcnVYUW6qaXLpeIlwdiCxZjDoeY1idiCEQkOwMWhPSyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwMkCxJO69VQ>? MmLoV2FPT0WU
human HOS cell NYHXbpgyT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NVn4UmZoUW6qaXLpeIlwdiCxZjDoeY1idiCKT2OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlIyPSEQvF2= MnPtV2FPT0WU
human 639-V cell Mn65S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NGTGTnFKdmirYnn0bY9vKG:oIHj1cYFvKDZ|OT3WJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4zOThizszN NFT4XlNUSU6JRWK=
human ES1 cell  NVPtfW5pT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NXHkbWZoUW6qaXLpeIlwdiCxZjDoeY1idiCHU{GgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlIzOSEQvF2= NHTvWnZUSU6JRWK=
human TE-15 cell  M4LYW2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MXPJcohq[mm2aX;uJI9nKGi3bXHuJHRGNTF3IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6yNlUh|ryP MYLTRW5ITVJ?
human LXF-289 cell Ml64S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MlPoTY5pcWKrdHnvckBw\iCqdX3hckBNYEZvMki5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4zPzdizszN NWLKcJJCW0GQR1XS
human CAL-12T cell MWPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NIXGcnFKdmirYnn0bY9vKG:oIHj1cYFvKEODTD2xNnQh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjJ|OTFOwG0> NXv3NnJ2W0GQR1XS
human T84 cell MVzHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MWnJcohq[mm2aX;uJI9nKGi3bXHuJHQ5PCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwMkSg{txO M4\uOXNCVkeHUh?=
human KYSE-450 cell Mmf5S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NUK2TFFMUW6qaXLpeIlwdiCxZjDoeY1idiCNWWPFMVQ2OCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwMk[3JO69VQ>? MmXQV2FPT0WU
human LCLC-103H cell M{TSfWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M1rjUGlvcGmkaYTpc44hd2ZiaIXtZY4hVEOOQz2xNFNJKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5|MTDuUS=> MoDHV2FPT0WU
human NCI-H810 cell M3\xOGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NEi4ZYdKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3IPFExKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5|MkKg{txO NGfFXGpUSU6JRWK=
human HUTU-80 cell NWTwVGZIT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M4f1UWlvcGmkaYTpc44hd2ZiaIXtZY4hUFWWVT24NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOzJ6IN88US=> NXPqV3R{W0GQR1XS
human NCI-H460 cell NF7uO4JIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MYfJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KNE[wJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4{OzNizszN NHnlUZVUSU6JRWK=
human HGC-27 cell M{nBZWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 Ml7MTY5pcWKrdHnvckBw\iCqdX3hckBJT0NvMkegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlM{QCEQvF2= NGjmTHNUSU6JRWK=
human HSC-2 cell MnP2S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MWPJcohq[mm2aX;uJI9nKGi3bXHuJGhUSy1{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6zOlMhdk1? M1;KfXNCVkeHUh?=
human IA-LM cell MmnOS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NFrBWW1KdmirYnn0bY9vKG:oIHj1cYFvKEmDLVzNJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4{QTNizszN NXHVc4dbW0GQR1XS
human HMV-II cell MYHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NHHhUGFKdmirYnn0bY9vKG:oIHj1cYFvKEiPVj3JTUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOzl2IN88US=> MWDTRW5ITVJ?
human COLO-679 cell MV7Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M{fIZ2lvcGmkaYTpc44hd2ZiaIXtZY4hS0:OTz22O|kh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjN7NDFOwG0> M3H1fHNCVkeHUh?=
human NCI-H2122 cell MUnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M{PEVGlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLViyNVIzKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC52MTFOwG0> MUjTRW5ITVJ?
human CAL-39 cell M{HpVWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NYn3cFJDUW6qaXLpeIlwdiCxZjDoeY1idiCFQVytN|kh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjRzMTFOwG0> MmrSV2FPT0WU
human SW954 cell NH\LR3BIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NHnVflhKdmirYnn0bY9vKG:oIHj1cYFvKFOZOUW0JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE41OzZizszN M1nKd3NCVkeHUh?=
human LCLC-97TM1 cell M1rOcGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 Mn\4TY5pcWKrdHnvckBw\iCqdX3hckBNS0yFLUm3WG0yKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC52NESg{txO NGDkSZhUSU6JRWK=
human KYSE-270 cell MVLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Ml25TY5pcWKrdHnvckBw\iCqdX3hckBMYVOHLUK3NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvPDR3IN88US=> M{LoenNCVkeHUh?=
human NB13 cell M3[zbGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MUHJcohq[mm2aX;uJI9nKGi3bXHuJG5DOTNiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkS0O{DPxE1? NYG1bpdMW0GQR1XS
human SK-LMS-1 cell MWHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MYnJcohq[mm2aX;uJI9nKGi3bXHuJHNMNUyPUz2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE43PDZizszN MXnTRW5ITVJ?
human SW620 cell NVvTPJh4T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NFSwdlNKdmirYnn0bY9vKG:oIHj1cYFvKFOZNkKwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE43PDhizszN MWXTRW5ITVJ?
human HCT-15 cell NIfp[IVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MnLmTY5pcWKrdHnvckBw\iCqdX3hckBJS1RvMUWgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlcyPyEQvF2= M4XVVXNCVkeHUh?=
human DU-145 cell NWPwNmlLT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MX7Jcohq[mm2aX;uJI9nKGi3bXHuJGRWNTF2NTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuO|IyKM7:TR?= MUnTRW5ITVJ?
human ST486 cell Mm\PS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M4T2cmlvcGmkaYTpc44hd2ZiaIXtZY4hW1R2OE[gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlczOSEQvF2= MVXTRW5ITVJ?
human A427 cell M{HYU2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NV7ySFNDUW6qaXLpeIlwdiCxZjDoeY1idiCDNEK3JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE45OjhizszN MlHWV2FPT0WU
human HT-1080 cell MVHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NXnZVm1LUW6qaXLpeIlwdiCxZjDoeY1idiCKVD2xNFgxKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC56NEKg{txO NIjrfJVUSU6JRWK=
human NCI-H2009 cell MXvHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MmnSTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEKwNFkh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjh4MjFOwG0> MmPLV2FPT0WU
human SK-LU-1 cell NHG4R21Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= Mo\ITY5pcWKrdHnvckBw\iCqdX3hckBUUy2OVT2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE45PjZizszN MYrTRW5ITVJ?
human SCC-4 cell MYfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MWPJcohq[mm2aX;uJI9nKGi3bXHuJHNESy12IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD64O|ch|ryP M4rxT3NCVkeHUh?=
human NCI-H1299 cell M2Xncmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M1rse2lvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVixNlk6KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC56ODFOwG0> NWW3RmRQW0GQR1XS
human NH-12 cell NF\ZNItIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M{\4XWlvcGmkaYTpc44hd2ZiaIXtZY4hVkhvMUKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlg6OSEQvF2= NUnWVW0{W0GQR1XS
human SK-UT-1 cell M2rnOmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NIHqWmdKdmirYnn0bY9vKG:oIHj1cYFvKFONLWXUMVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjh7MjFOwG0> NWPsU3FpW0GQR1XS
human Bel7402 M1fZb3Bzd2yrZnXyZZRqd25iYYPzZZk> M1m4flczKGh? NX\hb|hxSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDC[Yw4PDB{IHHmeIVzKDd{IHjyd{BjgSCFZXzsWIl1\XJiR3zvJIF{e2G7LDDJR|UxRTBwOTFOwG0> MYqyNlMzODN3NB?=
human A388 cell MUTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MVTJcohq[mm2aX;uJI9nKGi3bXHuJGE{QDhiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkm0JO69VQ>? M17WUnNCVkeHUh?=
human SW982 cell NWe2RphXT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NXfUdodoUW6qaXLpeIlwdiCxZjDoeY1idiCVV{m4NkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvQTl7IN88US=> Mle5V2FPT0WU

多くの細胞株試験データを見る場合、クリックしてください

体内試験 In a mouse xenograft model of RPMI 8226 cells, Epothilone B (2.5 mg/kg–4 mg/kg) prolongs survival and suppresses tumor growth. [4] Similarly, in mouse xenograft models of prostate cancer cells, including DU145 and PC3, Epothilone B at the same dose also inhibits tumor growth. [6]

お薦めの試験操作(参考用のみ)

キナーゼ試験:[1]
+ 展開

Tubulin polymerization assay:

Calf brain microtubule proteins (MTP) are purified, which includes approximately 15%–20% microtubule associated proteins. The buffer (MES buffer) used for the Epothilone B-microtubule studies contains 0.1 M 2-morpholinoethanesulfonic acid (MES), 1 mM EGTA, 0.5 mM MgCl2, and 3 M glycerol at pH 6.6. Samples for electron microscopy are placed on carbon-over-Parlodion-coated grids (300 mesh) and negatively stained with 2% uranyl acetate. Microtubule assembly in the presence or absence of Epothilone B is monitored spectrophotometrically by using a spectrophotometer equipped with a thermostatically regulated liquid circulator. The temperature is held at 35 °C and changes in turbidity (representative of polymer mass) are monitored at 350 nm. Effective concentration (EC0.01), defined as the interpolated concentration capable of inducing an initial slope of 0.01 OD/min rate, is calculated using the formula EC0.01 = concentration/slope and expressed as the mean with standard deviation obtained from three different concentrations.
細胞試験: [2]
+ 展開
  • 細胞株: KB3-1, KBV-1, Hela, and Hs578T cells
  • 濃度: 0–1 μM
  • 反応時間: 72 hours
  • 実験の流れ: For mitotic block and aberrant mitosis, cells are plated either in 48-well plates (for trypan blue and cell counting) or onto coverslips. After 24 hours, cells are treated with Epothilone B and scored at regular intervals. For the cytotoxicity analysis, cells are counted and scored as trypan blue positive or negative. Concurrently, coverslips andaliquots of cells in the culture supernatant are fixed and stained with Hoechst33342 in PBS. These cells are scored for cells blocked at the G2/M transition and aberrant mitosis.
    (参考用のみ)
動物試験:[4]
+ 展開
  • 動物モデル: Mice xenograft model of RPMI 8226 cells
  • 製剤: Dissolved in30% PEG-300
  • 投薬量: 2.5 mg/kg–4 mg/kg
  • 投与方法: Inject intravenously
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 102 mg/mL (200.91 mM)
Ethanol 102 mg/mL (200.91 mM)
Water slightly soluble or insoluble
体内 順序で溶剤を入れること:
30% PEG400+0.5% Tween80+5% propylene glycol
5 mg/mL

* 溶解度検測はSelleck技術部門によって行いますので、文献より提供された溶解度と差異がある可能性がありますが、生産工芸と不同ロット(lot)で起きる正常な現象ですから、ご安心ください。

化学情報

分子量 507.68
化学式

C27H41NO6S

CAS No. 152044-54-7
保管
in solvent
別名 N/A

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00715013 Completed Recurrent Glioblastoma Planned for Reoperation University of Zurich July 2008 Phase 1|Phase 2
NCT00442741 Withdrawn Solid Tumors Novartis Pharmaceuticals|Novartis July 2007 Phase 1
NCT00496600 Completed Refractory Malignancy University of Medicine and Dentistry of New Jersey|Novartis Pharmaceuticals|National Cancer Institute (NCI)|Rutgers, The State University of New Jersey July 2007 Phase 1
NCT00468260 Terminated Advanced Malignancies Novartis Pharmaceuticals|Novartis May 2007 Phase 1
NCT00448396 Completed Advanced Malignancies Novartis Pharmaceuticals|Novartis March 2007 Phase 1
NCT00407251 Completed Hormone Refractory Prostate Cancer British Columbia Cancer Agency February 2007 Phase 2

技術サポート

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

Handling Instructions

他の質問がある場合は、お気軽くお問合せください。

  • * 必須

Microtubule Associated信号経路図

相関Microtubule Associated製品

Tags: Patupilone (EPO906, Epothilone B)を買う | Patupilone (EPO906, Epothilone B) ic50 | Patupilone (EPO906, Epothilone B)供給者 | Patupilone (EPO906, Epothilone B)を購入する | Patupilone (EPO906, Epothilone B)費用 | Patupilone (EPO906, Epothilone B)生産者 | オーダーPatupilone (EPO906, Epothilone B) | Patupilone (EPO906, Epothilone B)化学構造 | Patupilone (EPO906, Epothilone B)分子量 | Patupilone (EPO906, Epothilone B)代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID